222 related articles for article (PubMed ID: 23737137)
21. Matrix Metalloproteinases on Severe COVID-19 Lung Disease Pathogenesis: Cooperative Actions of MMP-8/MMP-2 Axis on Immune Response through HLA-G Shedding and Oxidative Stress.
da Silva-Neto PV; do Valle VB; Fuzo CA; Fernandes TM; Toro DM; Fraga-Silva TFC; Basile PA; de Carvalho JCS; Pimentel VE; Pérez MM; Oliveira CNS; Rodrigues LC; Bastos VAF; Tella SOC; Martins RB; Degiovani AM; Ostini FM; Feitosa MR; Parra RS; Vilar FC; Gaspar GG; Rocha JJRD; Feres O; Arruda E; Maruyama SR; Russo EMS; Viana AL; Santos IKFM; Bonato VLD; Cardoso CRB; Tanus-Santos JE; Donadi EA; Faccioli LH; Dias-Baruffi M; Fernandes APM; Gerlach RF; Sorgi CA; On Behalf Of The Immunocovid Study Group
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625532
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity.
Mercuri FA; Maciewicz RA; Tart J; Last K; Fosang AJ
J Biol Chem; 2000 Oct; 275(42):33038-45. PubMed ID: 11032846
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a competitive enzyme-linked immunosorbent assay for measurements of soluble HLA-G protein.
Rasmussen M; Dahl M; Buus S; Djurisic S; Ohlsson J; Hviid TV
Tissue Antigens; 2014 Aug; 84(2):206-15. PubMed ID: 24785939
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
25. Mapping of matrix metalloproteinase cleavage sites on syndecan-1 and syndecan-4 ectodomains.
Manon-Jensen T; Multhaupt HA; Couchman JR
FEBS J; 2013 May; 280(10):2320-31. PubMed ID: 23384311
[TBL] [Abstract][Full Text] [Related]
26. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
Klein G; Vellenga E; Fraaije MW; Kamps WA; de Bont ES
Crit Rev Oncol Hematol; 2004 May; 50(2):87-100. PubMed ID: 15157658
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells.
Yamanegi K; Yamane J; Kobayashi K; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
Oncol Rep; 2012 Nov; 28(5):1585-90. PubMed ID: 22923031
[TBL] [Abstract][Full Text] [Related]
28. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10.
Nold M; Goede A; Eberhardt W; Pfeilschifter J; Mühl H
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):68-75. PubMed ID: 12616343
[TBL] [Abstract][Full Text] [Related]
29. New in Vivo Compatible Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitors.
Beutel B; Song J; Konken CP; Korpos E; Schinor B; Gerwien H; Vidyadharan R; Burmeister M; Li L; Haufe G; Sorokin L
Bioconjug Chem; 2018 Nov; 29(11):3715-3725. PubMed ID: 30277751
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticles targeting HLA-G for gene therapy in cancer.
Zidi I; Ben Amor N
Med Oncol; 2012 Jun; 29(2):1384-90. PubMed ID: 21499927
[TBL] [Abstract][Full Text] [Related]
31. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
32. Activation of fibroblast-derived matrix metalloproteinase-2 by colon-cancer cells in non-contact Co-cultures.
Ko K; Yazumi S; Yoshikawa K; Konda Y; Nakajima M; Chiba T; Takahashi R
Int J Cancer; 2000 Jul; 87(2):165-71. PubMed ID: 10861469
[TBL] [Abstract][Full Text] [Related]
33. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1.
Velasco-Loyden G; Arribas J; López-Casillas F
J Biol Chem; 2004 Feb; 279(9):7721-33. PubMed ID: 14672946
[TBL] [Abstract][Full Text] [Related]
34. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model.
Karagiannis ED; Popel AS
J Theor Biol; 2006 Jan; 238(1):124-45. PubMed ID: 16005020
[TBL] [Abstract][Full Text] [Related]
35. Metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 ectodomain decreases endocytic clearance of endometrial matrix metalloproteinase-2 and -9 at menstruation.
Selvais C; Gaide Chevronnay HP; Lemoine P; Dedieu S; Henriet P; Courtoy PJ; Marbaix E; Emonard H
Endocrinology; 2009 Aug; 150(8):3792-9. PubMed ID: 19406945
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site.
Suzuki M; Raab G; Moses MA; Fernandez CA; Klagsbrun M
J Biol Chem; 1997 Dec; 272(50):31730-7. PubMed ID: 9395517
[TBL] [Abstract][Full Text] [Related]
38. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme.
Toth M; Hernandez-Barrantes S; Osenkowski P; Bernardo MM; Gervasi DC; Shimura Y; Meroueh O; Kotra LP; Gálvez BG; Arroyo AG; Mobashery S; Fridman R
J Biol Chem; 2002 Jul; 277(29):26340-50. PubMed ID: 12004057
[TBL] [Abstract][Full Text] [Related]
39. Shedding of membrane type 1 matrix metalloproteinase in a human breast carcinoma cell line.
Harayama T; Ohuchi E; Aoki T; Sato H; Seiki M; Okada Y
Jpn J Cancer Res; 1999 Sep; 90(9):942-50. PubMed ID: 10551322
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of equine matrix metalloproteinase 2 and 9; and identification of the cellular sources of these enzymes in joints.
Clegg PD; Burke RM; Coughlan AR; Riggs CM; Carter SD
Equine Vet J; 1997 Sep; 29(5):335-42. PubMed ID: 9306058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
